130
Metz-Boutigue MH, Goumon Y, Lugardon K, Strub JM, Aunis D (1998) Antibacterial peptides are
present in chromaffin cell secretory granules. Cell Mol Neurobiol 18(2):249–266
Metz-Boutigue MH, Kieffer AE, Goumon Y, Aunis D (2003) Innate immunity: involvement of new
neuropeptides. Trends Microbiol 11(12):585–592
Ozawa K, Whalen EJ, Nelson CD, Mu Y, Hess DT, Lefkowitz RJ, Stamler JS (2008) S-nitrosylation
of beta-arrestin regulates beta-adrenergic receptor trafficking. Mol Cell 3:395–405
Pasqua T, Corti A, Gentile S, Pochini L, Bianco M, Metz-Boutigue MH, Cerra MC, Tota B,
Angelone T (2013) Full-length human chromogranin-A cardioactivity: myocardial, coronary,
and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts.
Endocrinology 154(9):3353–3365
Pasqua T, Tota B, Penna C, Corti A, Cerra MC, Loh YP, Angelone T (2015) pGlu-serpinin protects
the normotensive and hypertensive heart from ischemic injury. J Endocrinol 227(3):167–178
Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D, Losano G, Pagliaro P
(2006) Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and
pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 101(2):168–179
Penna C, Mognetti B, Tullio F, Gattullo D, Mancardi D, Pagliaro P, Alloatti G (2008) The platelet
activating factor triggers preconditioning-like cardioprotective effect via mitochondrial K-ATP
channels and redox-sensible signaling. J Physiol Pharmacol 59:47–54
Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F, Bassino E, Dolgetta S, Mahata SK,
Tota B, Pagliaro P (2010) Catestatin improves post-ischemic left ventricular function and
decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol 30(8):1171–1179
Perrelli MG, Tullio F, Angotti C, Cerra MC, Angelone T, Tota B, Alloatti G, Penna C, Pagliaro P
(2013) Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt,
PKCs, mitochondrial KATP channels and ROS signaling. Pflugers Arch 465(7):1031–1040
Petroff MG, Kim SH, Pepe S, Dessy C, Marbán E, Balligand JL, Sollott SJ (2010) Endogenous
nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes.
Nat Cell Biol 3(10):867–873
Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F,
Maseri A (2007) Myocardial production of chromogranin A in human heart: a new regulatory
peptide of cardiac function. Eur Heart J 28(9):1117–1127
Prendergast BD, Sagach VF, Shah AM (1997) Basal release of nitric oxide augments the Frank-
Starling response in the isolated heart. Circulation 96(4):1320–1329
Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP (2010) Vasostatin 1 activates
eNOS in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem
110(1):70–79
Reddy LG, Shi Y, Kutchai H, Filoteo AG, Penniston JT, Thomas DD (1999) An autoinhibitory pep-
tide from the erythrocyte Ca-ATPase aggregates and inhibits both muscle Ca-ATPase isoforms.
Biophys J 76(6):3058–3065
Satoh K, Matsu-Ura T, Enomoto M, Nakamura H, Michikawa T, Mikoshiba K (2011) Highly
cooperative dependence of sarco/endoplasmic reticulum calcium ATPase(SERCA) 2a pump
activity on cytosolic calcium in living cells. J Biol Chem 286:20591–20599
Schmidt AG, Edes I, Kranias EG (2001) Phospholamban: a promising therapeutic target in heart
failure? Cardiovasc Drugs Ther 15(5):387–396
Schneider F, Bach C, Chung H, Crippa L, Lavaux T, Bollaert PE, Wolff M, Corti A, Launoy A,
Delabranche X, Lavigne T, Meyer N, Garnero P, Metz-Boutigue MH (2012) Vasostatin-I, a
chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics,
and prognostic significance. Intensive Care Med 38(9):1514–1522
Shaul PW, Afshar S, Gibson LL, Sherman TS, Kerecman JD, Grubb PH, Yoder BA, McCurnin DC
(2002) Developmental changes in nitric oxide synthase isoform expression and nitric oxide
production in fetal baboon lung. Am J Physiol Lung Cell Mol Physiol 283(6):L1192–L1199
Stavrakis S, Scherlag BJ, Fan Y, Liu Y, Liu Q, Mao J, Cai H, Lazzara R, Po SS (2012) Antiarrhythmic
effects of vasostatin-1 in a canine model of atrial fibrillation. J Cardiovasc Electrophysiol
23(7):771–777
T. Angelone et al.